ES477977A1 - Procedimiento para la obtencion de nuevos derivados de anti-geno. - Google Patents

Procedimiento para la obtencion de nuevos derivados de anti-geno.

Info

Publication number
ES477977A1
ES477977A1 ES477977A ES477977A ES477977A1 ES 477977 A1 ES477977 A1 ES 477977A1 ES 477977 A ES477977 A ES 477977A ES 477977 A ES477977 A ES 477977A ES 477977 A1 ES477977 A1 ES 477977A1
Authority
ES
Spain
Prior art keywords
preparation
antigen
pharmaceutical compositions
compositions containing
antigen derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES477977A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27173419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES477977(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES477977A1 publication Critical patent/ES477977A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6062—Muramyl peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procedimiento para la obtención de nuevos derivados de antígeno, compuestos de un antígeno y un péptido de muramilo covalentemente ligado con él, en caso dado a través de un miembro puente, caracterizado porque un antígeno, en caso dado enlazado con un miembro puente, se condensa con péptidos de muramilo, en caso dado enlazados con miembros puente, donde una de las dos partes lleva un grupo amino, hidroxi o mercapto libre y la otra un grupo de ácido carboxílico.
ES477977A 1978-02-24 1979-02-22 Procedimiento para la obtencion de nuevos derivados de anti-geno. Expired ES477977A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH203578 1978-02-24
CH377778 1978-04-07
CH539478 1978-05-18

Publications (1)

Publication Number Publication Date
ES477977A1 true ES477977A1 (es) 1980-01-16

Family

ID=27173419

Family Applications (2)

Application Number Title Priority Date Filing Date
ES477977A Expired ES477977A1 (es) 1978-02-24 1979-02-22 Procedimiento para la obtencion de nuevos derivados de anti-geno.
ES483558A Expired ES483558A1 (es) 1978-02-24 1979-08-22 Procedimiento para la obtencion de derivados de sililgluco- saminas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES483558A Expired ES483558A1 (es) 1978-02-24 1979-08-22 Procedimiento para la obtencion de derivados de sililgluco- saminas

Country Status (20)

Country Link
EP (1) EP0003833B2 (es)
JP (1) JPS54141718A (es)
AR (1) AR223833A1 (es)
AT (1) AT364718B (es)
AU (1) AU527549B2 (es)
CA (1) CA1138436A (es)
DD (1) DD141616A5 (es)
DK (1) DK161026C (es)
ES (2) ES477977A1 (es)
FI (1) FI66878C (es)
GB (1) GB2015534A (es)
GR (1) GR77615B (es)
HU (1) HU182011B (es)
IL (1) IL56724A (es)
NO (2) NO151201C (es)
NZ (1) NZ189756A (es)
PL (1) PL123315B1 (es)
PT (1) PT69281A (es)
SU (1) SU1055312A3 (es)
ZA (1) ZA79893B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130516A (en) * 1978-03-31 1979-10-09 Yuuichi Yamamura Acyllnnacetylmuramylpeptide derivativeeantigen combination
FR2428050A1 (fr) * 1978-06-05 1980-01-04 Anvar Oligomeres de composes du type muramyl-peptide et medicaments les contenant
FR2428051A1 (fr) * 1978-06-05 1980-01-04 Anvar Nouveaux composes du type muramyl-peptide et medicaments les contenant
US4335111A (en) 1978-12-22 1982-06-15 Agence National De Valorisation De La Recherche (Anvar) Compounds associating peptidyl of aminoacyl residues to lipophilic groups and pharmaceutical compositions containing said new compounds
FR2446292A1 (fr) * 1979-01-12 1980-08-08 Anvar Muramyl-peptides fixes sur polymeres peptidiques et medicaments les contenant
FR2449697A1 (fr) * 1979-02-20 1980-09-19 Anvar Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
JPS5618996A (en) * 1979-06-21 1981-02-23 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
DK156252C (da) * 1979-07-31 1989-12-18 Fujisawa Pharmaceutical Co Analogifremgangsmaade til fremstilling af di-, tri- eller tetrapeptidderivater eller salte deraf
US4406889A (en) * 1980-02-15 1983-09-27 Ciba-Geigy Corporation Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use
EP0038153A3 (en) * 1980-04-15 1982-12-22 Beecham Group Plc Modified allergens
US4368190A (en) * 1980-04-17 1983-01-11 Merck & Co., Inc. Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
US4497729A (en) * 1980-12-01 1985-02-05 Fujisawa Pharmaceutical Co., Ltd. Peptide, process for preparation thereof and use thereof
FR2522967B1 (fr) * 1982-03-15 1986-03-07 Anvar Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
FR2558165B1 (fr) * 1984-01-17 1986-07-04 Anvar Nouveaux conjugues d'oligo-muramylpeptides et compositions biologiques les contenant pour l'activation des macrophages
FR2569984B1 (fr) * 1984-09-12 1987-08-14 Anvar Molecule synthetique contenant une pluralite d'epitopes distincts, procede pour son obtention et application a la production de polyvaccins
CN109640959B (zh) 2016-04-29 2023-03-17 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
KR20250007021A (ko) 2017-06-09 2025-01-13 추가이 세이야쿠 가부시키가이샤 N-치환 아미노산을 포함하는 펩타이드의 합성 방법
WO2020111238A1 (ja) * 2018-11-30 2020-06-04 中外製薬株式会社 ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH564031A5 (es) * 1968-03-29 1975-07-15 Anvar
US4186194A (en) * 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
CH613709A5 (en) * 1975-12-10 1979-10-15 Ciba Geigy Ag Process for the preparation of glucosamine derivatives
JPS52139018A (en) * 1976-03-10 1977-11-19 Anvar Immuno adjuvant and antiinfection adjuvant composed of mainly nnacetyll muramiccllalanyllddglutamic ester or nnacetyllmuramiccllalanylldd isoglutamic ester
FR2343482A1 (fr) * 1976-03-10 1977-10-07 Anvar La 2- (2-acetamido-2-deoxy-3-o-d-glucopyranosyl) -d-propionyl-l-seryl-d-isoglutamine et medicaments la contenant

Also Published As

Publication number Publication date
GR77615B (es) 1984-09-25
EP0003833B1 (de) 1983-07-20
AR223833A1 (es) 1981-09-30
AT364718B (de) 1981-11-10
JPH0130809B2 (es) 1989-06-22
HU182011B (en) 1983-12-28
NO151201C (no) 1985-02-27
SU1055312A3 (ru) 1983-11-15
DK161026B (da) 1991-05-21
IL56724A0 (en) 1979-05-31
NO793993L (no) 1979-08-27
IL56724A (en) 1982-12-31
JPS54141718A (en) 1979-11-05
FI66878C (fi) 1984-12-10
EP0003833A2 (de) 1979-09-05
DD141616A5 (de) 1980-05-14
AU4454679A (en) 1979-08-30
NO151088B (no) 1984-10-29
AU527549B2 (en) 1983-03-10
DK161026C (da) 1991-10-28
ES483558A1 (es) 1980-04-16
NO790626L (no) 1979-08-27
FI790584A7 (fi) 1979-08-25
FI66878B (fi) 1984-08-31
NO151088C (no) 1985-02-06
NO151201B (no) 1984-11-19
DK79779A (da) 1979-08-25
GB2015534A (en) 1979-09-12
EP0003833B2 (de) 1990-12-19
PT69281A (de) 1979-03-01
ATA142079A (de) 1981-04-15
EP0003833A3 (en) 1980-02-06
CA1138436A (en) 1982-12-28
PL123315B1 (en) 1982-10-30
NZ189756A (en) 1982-05-31
ZA79893B (en) 1980-03-26
PL213696A1 (es) 1980-07-14

Similar Documents

Publication Publication Date Title
ES477977A1 (es) Procedimiento para la obtencion de nuevos derivados de anti-geno.
ES2031806T3 (es) Factor de permeabilidad vascular humano.
DE3583008D1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
MX7235E (es) Procedimiento para preparar una solucion inyectable intravenosamente de globulina de suero inmune
DK160614C (da) Analogifremgangsmaade til fremstilling af vinblastinderivater og farmaceutisk acceptable salte deraf
BR0008741A (pt) Peptìdeo de hiv, antìgenos, composições de vacina, kit de imunoensaio e método de detecção de anticorpos induzidos por hiv
FI811745A7 (fi) Farmaseuttinen seos ja menetelmä sen valmistamiseksi.
BR0114036A (pt) Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv
ES554155A0 (es) Un procedimiento para la preparacion de un proteina envolvente de un virus de sindrome de inmunodeficiencia adquirida
DK362786A (da) Fremgangsmaade og midler til fremstilling af liposomer
FI860878A7 (fi) Aminohappojohdokset ja menetelmä niiden valmistamiseksi.
FR2522967B1 (fr) Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant
FI803849A7 (fi) Uudet asyylipeptidit, niistä valmistetut farmaseuttiset valmisteet, menetelmä niiden valmistamiseksi ja niiden käyttö.
FI813862A7 (fi) Uusia 8-aryylialkyyli-3- fenyyli-3- nortropanoleja, niiden happoadditiosuoloja, näitä sisältäviä lääkeainelääkeaineita ja menetelmiä niiden valmistamiseksi.
IT1177889B (it) Proteine umane,antisieri per esse,procedimento per prepararli e corre di di prova che li contengono
ATE46703T1 (de) Regionspezifische determinanten fuer vitamin-k abhaengiges knochenprotein.
FR2565985B1 (fr) Nouvelles substances biologiquement actives obtenues a partir de la caseine bovine, leur procede de preparation et les compositions qui les contiennent
FI921562A7 (fi) Gem-difosfonihapot, menetelmä niiden valmistamiseksi ja farmaseuttiset koostumukset, jotka sisältävät niitä
ES2054108T3 (es) Un metodo para estabilizar estropipato en una forma de dosificacion farmaceutica.
FI793375A7 (fi) Antikoagulantti, menetelmä sen valmistamiseksi ja sitä sisältävät farmaseuttiset valmisteet.
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
FI854178A7 (fi) 1,2,4-triatsolo-karbamaatti ja sen happoadditiosuolat, näiden valmistusmenetelmät ja lääkeaineet.
IT8025883A0 (it) Derivato della glicina,metodo per la sua preparazione e composizioni farmaceutiche che lo contengono
NL7903871A (nl) Werkwijze ter bereiding van een prostacycline bevattend farmaceutisch preparaat, alsmede als zodanig verkregen preparaten.
DE69129747D1 (de) In lösung bringen von proteinen in aktiver form

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970519